0001420800-25-000040
SEC filingEnovis reported 8.1% revenue growth but a net loss of $663.2M driven by a $548.5M goodwill impairment; Adjusted EBITDA margin improved to 17.4%.
For the nine months ended October 3, 2025, Enovis generated net sales of $1,672.3 million, an increase of 8.1% from $1,546.6 million in the prior year period. Growth was driven by strong existing business volumes across both segments, favorable foreign currency translation of 0.9%, and additional calendar days, partially offset by a $4.3 million impact from the divestiture of the hosiery business. Gross profit rose 14.0% to $995.8 million, with gross margin expanding 300 basis points to 59.5% due to improved product mix, supply chain productivity, and lower inventory fair value step-up amortization ($19.3 million decline). However, operating results were significantly impacted by a non-cash goodwill impairment charge of $548.5 million recognized in the third quarter, resulting in an operating loss of $622.1 million compared to a loss of $111.0 million last year. Net loss from continuing operations was $662.9 million, compared to $123.8 million in the prior year. Adjusted EBITDA, which excludes impairment and other items, increased 10.4% to $291.1 million, with margin improving 40 basis points to 17.4%. Interest expense declined due to higher interest income on cross-currency swaps, and the effective tax rate was negative due to non-deductible impairment and valuation allowance increases.
Prevention & Recovery (P&R): Net sales increased 5.3% to $854.1 million, driven by solid existing business volume growth and favorable currency, partly offset by the hosiery divestiture. Gross margin improved 180 bps to 53.7% on higher-margin product mix and supply chain productivity. The segment reported an operating loss of $223.2 million, largely reflecting a $229.9 million goodwill impairment. Excluding impairment, P&R's Adjusted EBITDA grew to $119.9 million (14.0% margin vs. 13.8% prior year) due to operating leverage.
Reconstructive (Recon): Net sales rose 11.2% to $818.2 million, benefiting from strong volume growth, favorable currency (1.1%), and extra calendar days. Gross margin expanded 410 bps to 65.6%, aided by a $19.3 million reduction in inventory step-up amortization. Operating loss of $398.9 million included a $318.6 million goodwill impairment and a $45.8 million charge for purchase of royalty interest. Adjusted EBITDA increased to $171.2 million (20.9% margin vs. 20.6% prior year) on higher gross profit and cost leverage.
Management did not provide specific forward guidance but highlighted adequate liquidity through cash flow and credit facilities ( $355 million available on revolver). Strategic priorities include continued investment in R&D, particularly in surgical productivity and computer-assisted surgery technologies, and pursuing tuck-in acquisitions. The company expects fourth-quarter seasonality benefits, though noting fewer calendar days. The recent divestiture of Dr Comfort Footcare Solutions will reduce P&R revenue going forward. Key risks include tariff impacts, foreign exchange volatility, and potential further impairment if market capitalization remains depressed.
Operating cash flow of $128.7M significantly exceeded the net loss of $(663.2M), reflecting large non-cash charges: goodwill impairment ($548.4M), depreciation and amortization ($217.4M), and stock-based compensation ($24.8M). This indicates the core business is generating cash despite GAAP loss.
Capex intensity remains high at $141.1M, outpacing operating cash flow, resulting in negative free cash flow (not explicitly stated but implicitly negative). Investing activities also included $26.9M for acquisitions and investments.
Working capital changes were modest: trade receivables decreased slightly, inventories grew $33.2M, and accounts payable increased $10.3M. The large prior-year acquisition cash outflow ($765.4M) did not recur in 2025.
Financing activities provided $20.5M, primarily from net borrowings on revolving credit facilities. No share repurchases or dividends were disclosed. Overall, the company relies on debt to fund capex and acquisitions.